RxDoctor Payments Data

Geovanie Arocho-Pagan, MD

Internal Medicine · Isabela, PRNPI 1881084770

Payments from drug & device makers

$1,248in general payments, 2019–2025

Across 25 payments — averaging $49.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$285
  • AstraZeneca$198
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$128
  • Johnson & Johnson$126
  • Bayer$125
  • Eisai Inc.$125
  • plus $262 from 7 others

What the payments were for

  • Food & beverage$1,248100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,248 in reported general payments places this provider in the 65th percentile of 1,043 internal medicine providers in Puerto Rico.

See all internal medicine providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$15,334
Medicare patients
20
Services billed
128

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol67$81,008
EliquisApixaban37$50,958
JanumetSitagliptin Phos/Metformin Hcl31$31,912
XareltoRivaroxaban12$20,157
JanuviaSitagliptin Phosphate16$16,757
BrilintaTicagrelor14$13,383
JardianceEmpagliflozin13$12,560
SynthroidLevothyroxine Sodium104$12,346
LantusInsulin Glargine,hum.Rec.Anlog125$10,079
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$8,560
Candesartan Cilexetil54$8,030
Humalog Mix 75-25Insulin Lispro Protamin/Lispro38$6,962
Candesartan-HydrochlorothiazidCandesartan/Hydrochlorothiazid36$6,957
Spiriva RespimatTiotropium Bromide11$5,898
Atorvastatin Calcium435$5,828

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Brilinta$198$94,39181 claims
Johnson & JohnsonXarelto$126$20,15712 claims
Boehringer IngelheimJardiance, Spiriva Respimat$285$18,45824 claims
Sanofi-aventis U.S. LLCLantus$12$10,079125 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,043 internal medicine providers in Puerto Rico.

Other internal medicine in Isabela

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →